These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 356968

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
    Chahinian AP, Goldberg J, Holland JF, Reisman A, Jaffrey IS, Mandel EM.
    Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
    [Abstract] [Full Text] [Related]

  • 3. Protection against chemotherapy toxicity by IV hyperalimentation.
    Issell BF, Valdivieso M, Zaren HA, Dudrick SJ, Freireich EJ, Copeland EW, Bodey GP.
    Cancer Treat Rep; 1978 Aug; 62(8):1139-43. PubMed ID: 99235
    [Abstract] [Full Text] [Related]

  • 4. Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.
    Bjornsson S, Takita H, Kuberka N, Preisler H, Catane H, Higby D, Henderson E.
    Cancer Treat Rep; 1978 Apr; 62(4):505-10. PubMed ID: 350388
    [Abstract] [Full Text] [Related]

  • 5. Chemo-immunotherapy for unresectable bronchogenic carcinoma.
    Sarna GP, Lowitz BB, Haskell CM, Dorey FJ, Cline MJ.
    Cancer Treat Rep; 1978 May; 62(5):681-7. PubMed ID: 350397
    [Abstract] [Full Text] [Related]

  • 6. Doxorubicin, cisplatin, and Corynebacterium parvum in non-small cell bronchogenic carcinoma.
    Drapkin R, Bjornsson S, Naeher C, Higby D, Caracandas J, Wallens WT, Kuberka N, Suh K, Siddiqi N, Henderson ES.
    Cancer Treat Rep; 1980 May; 64(12):1367-9. PubMed ID: 7193520
    [Abstract] [Full Text] [Related]

  • 7. Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group.
    J Thorac Cardiovasc Surg; 1985 Jun; 89(6):842-7. PubMed ID: 2860271
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Random prospective study cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non small cell lung cancer.
    Einhorn LH, Williams SD, Stevens EE, Bond WH, Chenoweth L.
    Cancer Treat Rep; 1982 Dec; 66(12):2005-11. PubMed ID: 6291763
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chemoimmunotherapy of small cell bronchogenic carcinoma with VP-16-213, ifosfamide, vincristine, adriamycin, and Corynebacterium parvum.
    Valdivieso M, Tenczynski TF, Rodriguez V, Burgess MA, Mountain CF, Barkley HT, Hersh EM, Bodey GP.
    Cancer; 1981 Jul 15; 48(2):238-44. PubMed ID: 6263454
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Immunotherapy of resectable lung cancer using Nocardia rubra cell wall skeleton].
    Ogura T.
    Gan To Kagaku Ryoho; 1983 Feb 15; 10(2 Pt 2):366-72. PubMed ID: 6349535
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.